Quantcast

Latest Adalimumab Stories

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-10-08 12:28:53

Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that despite the increasing percentage of rheumatoid arthritis (RA) patients treated with agents with a newer mechanism of action (MOA), three-quarters of DMARD-failure RA patients who are naive to biologics/Pfizer's Xeljanz are still initiated on tumor necrosis...

2014-10-08 08:28:04

Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Oct. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira(®) (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint. The primary endpoint was the Psoriasis Area and Severity Index (PASI) percent improvement from baseline to week 16 of treatment. At week 16,...

2014-10-06 08:28:13

-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct. 6, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. HUMIRA was approved in the United States in 2008 for...

2014-10-01 16:27:17

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel(®) (etanercept) and ABP 501 (adalimumab biosimilar) at the 23(rd) Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to...

2014-09-25 08:27:02

-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for reducing signs and symptoms, and achieving and...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-16 12:30:41

Rheumatologists Report that the Vast Majority of RA Patients Who are Candidates for Biologic Treatment Receive a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the percentage of rheumatoid arthritis (RA) patients treated with a biologic agent by rheumatologists has remained relatively constant since 2012 in the major European markets (France, Germany, Italy, Spain and the United Kingdom)....

2014-09-16 12:30:11

The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion in 2013 to over $18.2 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. TNF-alpha inhibitors...

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.